COVID-19 deaths in children and young people in England, March 2020 to December 2021: An active prospective national surveillance study.
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
17
05
2022
accepted:
05
10
2022
entrez:
8
11
2022
pubmed:
9
11
2022
medline:
11
11
2022
Statut:
epublish
Résumé
Coronavirus Disease 2019 (COVID-19) deaths are rare in children and young people (CYP). The high rates of asymptomatic and mild infections complicate assessment of cause of death in CYP. We assessed the cause of death in all CYP with a positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) test since the start of the pandemic in England. CYP aged <20 years who died within 100 days of laboratory-confirmed SARS-CoV-2 infection between 01 March 2020 and 31 December 2021 in England were followed up in detail, using national databases, surveillance questionnaires, post-mortem reports, and clinician interviews. There were 185 deaths during the 22-month follow-up and 81 (43.8%) were due to COVID-19. Compared to non-COVID-19 deaths in CYP with a positive SARS-CoV-2 test, death due to COVID-19 was independently associated with older age (aOR 1.06 95% confidence interval (CI) 1.01 to 1.11, p = 0.02) and underlying comorbidities (aOR 2.52 95% CI 1.27 to 5.01, p = 0.008), after adjusting for age, sex, ethnicity group, and underlying conditions, with a shorter interval between SARS-CoV-2 testing and death. Half the COVID-19 deaths (41/81, 50.6%) occurred within 7 days of confirmation of SARS-CoV-2 infection and 91% (74/81) within 30 days. Of the COVID-19 deaths, 61 (75.3%) had an underlying condition, especially severe neurodisability (n = 27) and immunocompromising conditions (n = 12). Over the 22-month surveillance period, SARS-CoV-2 was responsible for 1.2% (81/6,790) of all deaths in CYP aged <20 years, with an infection fatality rate of 0.70/100,000 SARS-CoV-2 infections in this age group estimated through real-time, nowcasting modelling, and a mortality rate of 0.61/100,000. Limitations include possible under-ascertainment of deaths in CYP who were not tested for SARS-CoV-2 and lack of direct access to clinical data for hospitalised CYP. COVID-19 deaths remain extremely rare in CYP, with most fatalities occurring within 30 days of infection and in children with specific underlying conditions.
Sections du résumé
BACKGROUND
Coronavirus Disease 2019 (COVID-19) deaths are rare in children and young people (CYP). The high rates of asymptomatic and mild infections complicate assessment of cause of death in CYP. We assessed the cause of death in all CYP with a positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) test since the start of the pandemic in England.
METHODS AND FINDINGS
CYP aged <20 years who died within 100 days of laboratory-confirmed SARS-CoV-2 infection between 01 March 2020 and 31 December 2021 in England were followed up in detail, using national databases, surveillance questionnaires, post-mortem reports, and clinician interviews. There were 185 deaths during the 22-month follow-up and 81 (43.8%) were due to COVID-19. Compared to non-COVID-19 deaths in CYP with a positive SARS-CoV-2 test, death due to COVID-19 was independently associated with older age (aOR 1.06 95% confidence interval (CI) 1.01 to 1.11, p = 0.02) and underlying comorbidities (aOR 2.52 95% CI 1.27 to 5.01, p = 0.008), after adjusting for age, sex, ethnicity group, and underlying conditions, with a shorter interval between SARS-CoV-2 testing and death. Half the COVID-19 deaths (41/81, 50.6%) occurred within 7 days of confirmation of SARS-CoV-2 infection and 91% (74/81) within 30 days. Of the COVID-19 deaths, 61 (75.3%) had an underlying condition, especially severe neurodisability (n = 27) and immunocompromising conditions (n = 12). Over the 22-month surveillance period, SARS-CoV-2 was responsible for 1.2% (81/6,790) of all deaths in CYP aged <20 years, with an infection fatality rate of 0.70/100,000 SARS-CoV-2 infections in this age group estimated through real-time, nowcasting modelling, and a mortality rate of 0.61/100,000. Limitations include possible under-ascertainment of deaths in CYP who were not tested for SARS-CoV-2 and lack of direct access to clinical data for hospitalised CYP.
CONCLUSIONS
COVID-19 deaths remain extremely rare in CYP, with most fatalities occurring within 30 days of infection and in children with specific underlying conditions.
Identifiants
pubmed: 36346784
doi: 10.1371/journal.pmed.1004118
pii: PMEDICINE-D-22-01661
pmc: PMC9642873
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1004118Informations de copyright
Copyright: © 2022 Bertran et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Philos Trans R Soc Lond B Biol Sci. 2021 Jul 19;376(1829):20200279
pubmed: 34053254
Lancet Child Adolesc Health. 2022 May;6(5):e16-e17
pubmed: 35364023
Lancet Child Adolesc Health. 2021 May;5(5):e12-e13
pubmed: 33713603
Sci Rep. 2021 May 13;11(1):10231
pubmed: 33986390
Arch Dis Child. 2020 Sep;105(9):857-863
pubmed: 32209555
Clin Infect Dis. 2017 Jul 15;65(2):308-314
pubmed: 28605414
Lancet Infect Dis. 2022 Jan;22(1):35-42
pubmed: 34461056
Lancet Child Adolesc Health. 2021 Jun;5(6):417-427
pubmed: 33740430
Acta Paediatr. 2020 Jun;109(6):1088-1095
pubmed: 32202343
Pediatr Infect Dis J. 2010 Apr;29(4):310-3
pubmed: 20216475
Public Health. 2021 May;194:163-166
pubmed: 33945929
Lancet Reg Health Eur. 2021 Apr;3:100075
pubmed: 34027512
BMJ. 2022 Mar 29;376:o831
pubmed: 35351678
Aging (Albany NY). 2021 Aug 18;13(16):19954-19962
pubmed: 34411000
BMJ. 2020 Aug 27;370:m3249
pubmed: 32960186
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
Nat Med. 2022 Jan;28(1):193-200
pubmed: 34931076
J Paediatr Child Health. 2022 Mar;58(3):432-439
pubmed: 34546612
Can J Infect Dis Med Microbiol. 2022 Mar 16;2022:2737719
pubmed: 35340920
Arch Dis Child. 2020 Dec;105(12):1180-1185
pubmed: 32796006
Nat Med. 2022 Jan;28(1):185-192
pubmed: 34764489
Pediatrics. 2021 Nov;148(5):
pubmed: 34385349
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Lancet Infect Dis. 2021 Dec;21(12):1629-1630
pubmed: 34838221
Mil Med Res. 2020 Apr 4;7(1):17
pubmed: 32245396
EClinicalMedicine. 2022 Feb;44:101287
pubmed: 35169689
Arch Dis Child. 2022 Jan;107(1):14-20
pubmed: 34911683